THE 2024 REVISED McDonald Criteria for multiple sclerosis (MS) diagnosis were explained in detail during a joint session ...

Frexalimab, an investigational second-generation CD40 ligand (CD40L) inhibitor, led to fewer new gadolinium-enhancing T1-weighted lesions in relapsing multiple sclerosis (MS), a phase II trial showed.

Historically, sex-related differences have been underexplored in neurology. It is important to highlight the distinction ...